A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: The CONTAIN study

British Journal of Ophthalmology

Volumn 99, Issue 6, 2015, Pages 848-852

  Pitcher, John D ^a   Witkin, Andre J ^a   DeCroos, Francis Char ^a   Ho, Allen C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ADULT; ARTICLE; CENTRAL MACULAR THICKNESS; CENTRAL SEROUS RETINOPATHY; CHRONIC CENTRAL SEROUS CHORIORETINOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE DISEASE; HUMAN; MALE; MEAN CHOROIDAL THICKNESS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYSTEMIC DISEASE; TREATMENT DURATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; BLOOD RETINA BARRIER; CAPILLARY PERMEABILITY; CENTRAL SEROUS CHORIORETINOPATHY; CHRONIC DISEASE; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PHYSIOLOGY; SUBRETINAL FLUID;

ADULT; ANGIOGENESIS INHIBITORS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; CENTRAL SEROUS CHORIORETINOPATHY; CHRONIC DISEASE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 84930384633     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-306018     Document Type: Article

References (26)

1. Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmol 2008;115:169-73.
2. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967;63:1-139.
3. Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. CurrOpinOphthalmol 2011;22:166-73.
4. Gilbert CM, Owens SL, Smith PD, et al. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 1984;68:815-20.
5. Singer M. Non-steroidal anti-inflammatory topical therapy speeds recovery in central serous chorioretinopathy. AAO 2013 meeting, New Orleans. Unpublished data.
6. Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1979;63:674-7.
7. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288-98.
8. Bae SH, Heo JW, Kim C, et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. OphthalmoL 2014;121:558-65.
9. Bousquet E, Beydoun T, Zhao M, et al. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy. A pilot study. Retina 2013;33:2096-102.
10. Maier M, Sumpfe S, Feucht N, et al. Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy. Ophthalmologe 2014;111:173-80.
11. Chiang A, Regillo CD. Preferred therapies for neovascular age-related macular degeneration. CurrOpinOphthalmol 2011;22:199-204.
12. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654-61.
13. Lim JW, Kim MU, Shin M-C. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 2010;30:1465-71.
14. Kim H-S, Lee JH. The short-term effect of intravitreal bevacizumab for treatment of central serous chorioretinopathy. J Korean OphthalmolSoc 2010;51:860-4.
15. Lim JW, Ryu SJ, Shin M-C. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol 2010;24:155-8.
16. Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 2011;152:784-92.
17. Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 2010;35:91-8.
18. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667-8.
19. Browning DJ, Kaiser PK, Rosenfeld PJ, et al. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 2012;154:222-6.
20. Chung Y-R, Seo EJ, Lew HM, et al. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye 2013;27:1339-46.
21. Zhang F, Tang Z, Hou X, et al. VEGF-B is dispensible for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 2009;106:6152-7.
22. Clark DE, Smith SK, Licence D, et al. Comparison of expression patterns for placena growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol 1998;159:459-67.
23. Feeney SA, Simpson DA, Gardiner TA, et al. Role of vascular endothelial growth factor and placental growth factors during retinal vascular development and hyaloid regression. Invest Ophthalmol Vis Sci 2003;44:839-47.
24. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83.
25. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmol 2012;119:2537-48.
26. Imamura Y, Fujiwara T, Margolis R, et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009;29:1469-73.